ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31

ACTUATE THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.60−0.01 (-0.99%)

Close on Oct 19, 2026

Market cap: $14.30M
P/E (TTM): –
Dividend yield: –

ACTUATE THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	10	19	22
General & Administrative	12	6.48	3.27
Operating Expenses	22	25	25
Operating Income	-22	-25	-25
Interest Expense	0.02	0.02	0.04
Interest & Investment Income	0.29	0.22	0.35
Other Non-Operating Income	0.27	-2.12	0.23
Income Tax Expense	0.00	0.00	0
Net Income	-22	-27	-25
EPS (Basic)(per share)	-1.06	-3.26	-17.24
EPS (Diluted)(per share)	-1.06	-3.26	-17.24
Shares Outstanding (Basic, Weighted)(shares)	21	8.37	1.43
Shares Outstanding (Diluted, Weighted)(shares)	21	8.37	1.43

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -553.7%

Financial strength

Current ratio: 1.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 116.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 14.46
Dividend yield: –